笔记详情
标题
主要终点与次要终点描述（Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma）
内容
The primary efficacy end point was investigator assessed clinical
benefit rate (CBR), defined as the proportion of patients
with a complete response (CR) or partial
response (PR) or stable disease (SD) ≥24 weeks according to RECIST (15).
Tumor assessments were scheduled every 8 weeks until disease
progression. Secondary end points included PFS, objective
response rate (ORR; CR + PR), duration of
response, time to treatment failure (TTF) and OS. Subgroup analyses for
key efficacy
end points were also performed for exploratory
purposes.
点击翻译
来源
Jpn. J. Clin. Oncol. (2012) 42 (9): 836-844.
类别
领域
Cancer/Oncology
关键词
